Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.
about
Structural basis for molecular recognition of folic acid by folate receptorsQuantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligandsTargeting folate receptor alpha for cancer treatmentAntimitotic drugs in the treatment of cancerNanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinomaMechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic deliveryFarletuzumab in lung cancerMultifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilitiesOrganelle targeting: third level of drug targetingIntraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection.Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognitionThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsBlood-based Tumor Markers in Lung CancerLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringTargeted immune therapy of ovarian cancerCan nanotechnology potentiate photodynamic therapy?Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapyTargeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNACellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticlesEffects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal Doxorubicin in vitroFolate-conjugated boron nitride nanospheres for targeted delivery of anticancer drugsTargeting and Photodynamic Killing of Cancer Cell by Nitrogen-Doped Titanium Dioxide Coupled with Folic AcidFolate receptor-targeted ultrasonic PFOB nanoparticles: Synthesis, characterization and application in tumor-targeted imaging.Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapyMolecular photoacoustic imaging of breast cancer using an actively targeted conjugated polymer.Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrinThe Interactions between L-tyrosine based nanoparticles decorated with folic acid and cervical cancer cells under physiological flowA quantitative relaxometric version of the ELISA test for the measurement of cell surface biomarkers.Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement.Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging.Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potentialRational design of "heat seeking" drug loaded polypeptide nanoparticles that thermally target solid tumors.Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer.The assembly state between magnetic nanosensors and their targets orchestrates their magnetic relaxation responseA Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in MiceExpression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.
P2860
Q24307935-3E3EE2A1-A1B6-432E-BDA5-82643C0A67DDQ24655544-F4D6AD07-80A8-444B-8B58-81247D1364C6Q26744215-5D1DB59D-C094-4EB3-8811-FABF24FDCC5BQ26777317-032721D5-F45D-4758-B6F5-37958321DB00Q26823523-4C6DEEDB-DF36-4AE6-9A02-A79F68494F21Q26852723-B3E239B9-0B3D-4FA2-80D9-40A55F7ED7ADQ26997008-321F5ECF-1DCA-48E6-9B98-2F4CE991F878Q27011598-ED00A2C2-F406-451A-BA1A-D7EA9C4D17E6Q27014902-04A5E966-9DB0-47D4-AF4C-248FDABA8AE6Q27308955-CDCC3A8B-CD10-4D1C-87B9-6C250B7EB43BQ27679502-B96F9B02-0B91-4DE7-A49C-32A7C1D967A0Q28066801-6FB7EC07-06F1-43EE-85AE-554A830AC833Q28072736-44BF72A3-ED01-4951-8E28-1BAF8364FE15Q28076191-EEE09D93-BCCB-49C3-AF31-1A04497DA03FQ28082828-C7102167-43AA-4F04-BC17-49A31F625C56Q28388084-D09ADBA5-3E76-443F-82F2-BDAAC67C862AQ28397980-11A80D5D-4179-40DF-B946-508E70C68019Q28478596-2C415B47-D133-4C94-B000-D5F32EBEDF54Q28538811-926478B7-07DA-4249-9943-6154F63EF9F4Q28741592-858C1445-B34E-4C1B-84CC-BE962CF0D1C6Q28829837-7AB547CF-7CA5-4E06-AE18-638E49219D7AQ29248436-F54AB055-9C4F-464E-8EEB-6C65EA4A58D5Q30356285-311B8CFA-CF96-4366-857F-5A21A2AC0E70Q30365844-BFFA0331-3410-4E71-9CF7-C96A81D61146Q30390185-14A67EAD-F5CE-422A-AE34-052D2D200AF5Q30420538-150BEDE5-5D61-4387-865F-9FA877786DC2Q30528396-54614550-0FE1-4847-ACA0-68D5613CA647Q30529631-D9D59A3C-D224-403E-934E-8B8C0AE1BA56Q30774704-1F40C951-FE5B-4FFC-AFE4-0BC356B9F287Q31169933-80D44A05-6E86-43EF-B4BD-3E761EEE82FDQ33433508-55C29D23-4669-4DA8-85A0-9372EB0A6920Q33484181-DADB1895-241A-4BED-A8DD-0DDF1351675BQ33593041-CE5D0AFA-0DC5-4D64-AF32-C6D44C4B0A8FQ33618570-E96E9FE6-E663-4CAB-AC5C-38E244935859Q33629980-989A55DB-EF91-4F0C-997D-E2B21B8947C6Q33734661-EE949385-546E-4E72-9D11-B87264064222Q33812669-7AEC70B1-9B7E-43F6-9F0F-89FB4B48A960Q33826648-BC11A3D6-6B84-416A-8276-E8FFF2698A95Q33851549-7387F41D-8D67-4802-9EB9-5253B3E9634BQ33914066-C2BF6886-41BC-4296-8DCD-A065A9753B1C
P2860
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Folate receptor expression in ...... ive radioligand binding assay.
@ast
Folate receptor expression in ...... ive radioligand binding assay.
@en
Folate receptor expression in ...... ive radioligand binding assay.
@nl
type
label
Folate receptor expression in ...... ive radioligand binding assay.
@ast
Folate receptor expression in ...... ive radioligand binding assay.
@en
Folate receptor expression in ...... ive radioligand binding assay.
@nl
prefLabel
Folate receptor expression in ...... ive radioligand binding assay.
@ast
Folate receptor expression in ...... ive radioligand binding assay.
@en
Folate receptor expression in ...... ive radioligand binding assay.
@nl
P2093
P356
P1476
Folate receptor expression in ...... ive radioligand binding assay.
@en
P2093
Christopher P Leamon
Elaine Westrick
Jeffrey D Lewis
Mary Jo Turk
Nikki Parker
Philip S Low
P304
P356
10.1016/J.AB.2004.12.026
P407
P577
2005-03-01T00:00:00Z